- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope | ||
| Fr | Inside the growing world of biopharma prediction markets | ||
| Fr | Xenon Pharmaceuticals pauses phase 3 depression trials after psychosis events | ||
| Fr | BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data | ||
| Fr | Inflammation biotech Electra Therapeutics charges up with $350M from upsized IPO | ||
| Do | Goa Therapeutics launches with 'immeasurably huge' vision of creating Narcan for alcohol | ||
| Do | After one failed acquisition attempt, Lisata finds lifeline in Marea merger | ||
| Do | North Immunology goes public via reverse merger as eczema drug heads toward clinic | ||
| Do | Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive | ||
| Do | SK pens $315M pact with fellow South Korean company for Parkinson's prospect | ||
| Do | Longeveron's phase 2b stem cell flop spurs cost cutting, exploration of 'all options' | ||
| Mi | Novartis ends ALS program after phase 2 flop, adding to R&D woes | ||
| Mi | Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier | ||
| Di | FDA launches pilot program to speed up sluggish phase 1 trials | ||
| Di | Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope | ||
| Di | Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech | ||
| Di | Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail | ||
| Di | GSK doubles down on Chimagen with $750M multiple myeloma wager | ||
| Di | Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis | ||
| Di | J&J's Contineum-partnered depression drug flunks another phase 2 test | ||
| Mo | Lilly cans early experimental obesity drug after 'high bar' not met | ||
| Mo | Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi | ||
| Mo | Electra Therapeutics aims for $342M IPO to power inflammatory drug's push through phase 3 | ||
| Mo | Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon | ||
| Mo | Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.